First Republic Investment Management, Inc. Neurocrine Biosciences Inc Transaction History

First Republic Investment Management, Inc.

$34.7 Billion
Q3 2023

A detailed history of First Republic Investment Management, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, First Republic Investment Management, Inc. holds 7,789 shares of NBIX stock, worth $835,136. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,789

Previous 7,963 2.19%

Holding current value

$835,136

Previous $750,000 16.8%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$94.02 - $117.1 $16,359 - $20,375	-174 Reduced 2.19%	7,789 $876,000
Q2 2023 Jul 28, 2023	SELL	$89.53 - $104.87 $273,693 - $320,587	-3,057 Reduced 27.74%	7,963 $750,000
Q1 2023 May 11, 2023	SELL	$94.11 - $123.02 $4,611 - $6,027	-49 Reduced 0.44%	11,020 $1.12 Million
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $12,059 - $14,357	113 Added 1.03%	11,069 $1.32 Million
Q3 2022 Nov 03, 2022	SELL	$92.03 - $107.81 $19,050 - $22,316	-207 Reduced 1.85%	10,956 $1.16 Million
Q2 2022 Aug 16, 2022	BUY	$75.79 - $100.07 $23,570 - $31,121	311 Added 2.87%	11,163 $1.09 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $303,565 - $397,253	4,190 Added 62.89%	10,852 $1.02 Million
Q4 2021 Feb 09, 2022	SELL	$79.65 - $106.22 $192,195 - $256,308	-2,413 Reduced 26.59%	6,662 $567,000
Q3 2021 Nov 12, 2021	BUY	$86.18 - $99.03 $118,325 - $135,968	1,373 Added 17.83%	9,075 $870,000
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $149,526 - $170,995	1,672 Added 27.73%	7,702 $750,000
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $190,902 - $260,292	-2,180 Reduced 26.55%	6,030 $586,000
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $2,259 - $2,816	-26 Reduced 0.32%	8,210 $787,000
Q3 2020 Nov 12, 2020	BUY	$96.16 - $135.15 $81,639 - $114,742	849 Added 11.49%	8,236 $792,000
Q2 2020 Aug 13, 2020	BUY	$85.09 - $130.36 $38,801 - $59,444	456 Added 6.58%	7,387 $901,000
Q1 2020 May 13, 2020	BUY	$75.11 - $113.76 $306,674 - $464,482	4,083 Added 143.36%	6,931 $600,000
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $25,432 - $34,741	293 Added 11.47%	2,848 $306,000
Q3 2019 Nov 08, 2019	SELL	$83.82 - $101.5 $723,031 - $875,539	-8,626 Reduced 77.15%	2,555 $230,000
Q2 2019 Aug 07, 2019	BUY	$72.24 - $91.27 $807,715 - $1.02 Million	11,181 New	11,181 $944,000
Q4 2018 Feb 12, 2019	SELL	$68.32 - $124.36 $1.6 Million - $2.92 Million	-23,491 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$98.88 - $125.85 $18,589 - $23,659	-188 Reduced 0.79%	23,491 $2.89 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $451 - $635	6 Added 0.03%	23,679 $2.33 Million
Q1 2018 May 10, 2018	BUY	$75.88 - $92.43 $4,704 - $5,730	62 Added 0.26%	23,673 $1.96 Million
Q4 2017 Feb 09, 2018	SELL	$58.53 - $77.59 $1.39 Million - $1.84 Million	-23,692 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $1.14 Million - $1.45 Million	23,692	23,692 $1.45 Million

Others Institutions Holding NBIX

# of Institutions

655

Shares Held

96.6M

Call Options Held

282K

Put Options Held

281K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $10.3B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.

Account

First Republic Investment Management, Inc. Neurocrine Biosciences Inc Transaction History